Publication date: May 01, 2025
Respiratory viral infections (RVIs) are associated with elevated cardiovascular risk; however, less is known about cardiac complications after hospitalization for respiratory syncytial virus (RSV) vs other vaccine-preventable RVIs (COVID-19 or influenza). To compare the risk of acute cardiovascular complications in adults hospitalized for RSV vs COVID-19 or influenza. This population-based cross-sectional study, conducted before RSV vaccination rollout in Singapore, assessed all adults hospitalized for RSV or influenza (January 1, 2017, to June 30, 2024) and all adults hospitalized for COVID-19 during Omicron XBB/JN. 1 transmission (January 1, 2023, to June 30, 2024). Hospitalization for RSV, influenza (vaccinated or unvaccinated), or COVID-19 (boosted [≥3 vaccine doses] or unboosted [
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Cardiac Events |
| disease | MESH | COVID-19 |
| disease | MESH | Influenza |
| disease | MESH | viral infections |
| disease | MESH | cardiovascular risk |
| disease | MESH | complications |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Methylphenidate |
| drug | DRUGBANK | Troleandomycin |
| drug | DRUGBANK | Sodium hydroxide |
| disease | MESH | Respiratory Syncytial Virus Infections |